Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

The School of Medicine is a major international centre for teaching and research, and committed to the pursuit of improved human health. We combine progressive healthcare education and patient care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report) and keeping the price target at $91.00. Ryan Zimmerman’s rating is based on a combination of ...

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

Globus Spirits surged 17.53% after the Indian government eased norms for rice supply to ethanol distilleries. The Ministry of Consumer Affairs, Food and Public Distribution on 17 January 2025 notified ...